全文获取类型
收费全文 | 208086篇 |
免费 | 4465篇 |
国内免费 | 2496篇 |
专业分类
耳鼻咽喉 | 1335篇 |
儿科学 | 7084篇 |
妇产科学 | 3373篇 |
基础医学 | 20455篇 |
口腔科学 | 2159篇 |
临床医学 | 16680篇 |
内科学 | 35750篇 |
皮肤病学 | 964篇 |
神经病学 | 17828篇 |
特种医学 | 10001篇 |
外国民族医学 | 29篇 |
外科学 | 32306篇 |
综合类 | 8326篇 |
现状与发展 | 9篇 |
一般理论 | 3篇 |
预防医学 | 20326篇 |
眼科学 | 3643篇 |
药学 | 13066篇 |
31篇 | |
中国医学 | 2638篇 |
肿瘤学 | 19041篇 |
出版年
2024年 | 135篇 |
2023年 | 633篇 |
2022年 | 1618篇 |
2021年 | 2086篇 |
2020年 | 1438篇 |
2019年 | 1256篇 |
2018年 | 23023篇 |
2017年 | 18410篇 |
2016年 | 20462篇 |
2015年 | 2441篇 |
2014年 | 2713篇 |
2013年 | 2478篇 |
2012年 | 9363篇 |
2011年 | 23663篇 |
2010年 | 20434篇 |
2009年 | 12817篇 |
2008年 | 21114篇 |
2007年 | 23385篇 |
2006年 | 2151篇 |
2005年 | 3700篇 |
2004年 | 4428篇 |
2003年 | 5360篇 |
2002年 | 3370篇 |
2001年 | 1041篇 |
2000年 | 1150篇 |
1999年 | 907篇 |
1998年 | 631篇 |
1997年 | 656篇 |
1996年 | 435篇 |
1995年 | 433篇 |
1994年 | 418篇 |
1993年 | 232篇 |
1992年 | 259篇 |
1991年 | 308篇 |
1990年 | 356篇 |
1989年 | 255篇 |
1988年 | 202篇 |
1987年 | 153篇 |
1986年 | 141篇 |
1985年 | 121篇 |
1984年 | 88篇 |
1983年 | 59篇 |
1982年 | 51篇 |
1980年 | 52篇 |
1974年 | 38篇 |
1969年 | 33篇 |
1938年 | 60篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
82.
Alexis A Gintowt Jeffrey J Germer P Shawn Mitchell Joseph D C Yao 《Journal of clinical virology》2005,34(2):155-157
BACKGROUND: The current manual sample processing method recommended for use with the TRUGENE HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare LLC, Tarrytown, NY) is labor-intensive and may be prone to specimen cross-contamination. Recent evaluations of the MagNA Pure LC (MP; Roche Applied Science, Indianapolis, IN) suggest that it is suitable for automated, contamination-free extraction and purification of viral nucleic acids from large-volume (1.0 mL) serum or plasma specimens. OBJECTIVES: We evaluated the MP Total Nucleic Acid Isolation Kit--Large Volume (Roche Applied Science) in conjunction with TRUGENE HBV to establish the analytical sensitivity (threshold titer) of the assay, in HBV DNA International Units (IU)/mL, for obtaining consistent, interpretable sequence data from TRUGENE HBV. STUDY DESIGN: HBV analytical standards, prepared as 10 replicates (1.0 mL each) at each of the following concentrations: 200, 1000, 5000, and 10,000 IU/mL, were processed by MP and analyzed by TRUGENE HBV according to manufacturer's instructions. Performance of TRUGENE HBV used in conjunction with MP sample processing was evaluated further using 22 clinical serum specimens containing low titers of HBV DNA. RESULTS: All replicates of HBV analytical standards at 1000, 5000, and 10,000 IU/mL yielded interpretable TRUGENE HBV sequences, whereas interpretable sequences were obtained in 90% (9 of 10) of the replicates at 200 IU/mL. TRUGENE HBV sequences were interpretable in 86% (19 of 22) of the clinical specimens studied. CONCLUSIONS: MP sample processing is efficient and suitable for use with TRUGENE HBV. When combined with MP sample processing, TRUGENE HBV yielded interpretable sequences from HBV analytical standards and clinical serum specimens with HBV DNA titers of > or =200 IU/mL. 相似文献
83.
Objective: To study the diagnostic value of T2^*-weighted first-pass perfusion imaging in breast tumors. Methods: We analyzed the magnetic resonance imaging (MRI) information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^*-weighted first-pass perfusion imaging. The curve's maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results: Malignant breast lesions showed higher maximal signal intensity drop rate (44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001) than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions (23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05). Conclusion: The T2^*-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis. 相似文献
84.
85.
Xiaoping Chen Guoxiang Yao Department of Surgery Tongji Hospital Tongji Medical College Huazhong University of Science Technology Wuhan China 《中德临床肿瘤学杂志》2007,(2)
Objective: We compare the outcome of palliative pancreaticoduodenectomy and palliative surgical bypass in patients with advanced pancreatic carcinoma in our hospital. Recent published related articles are also reviewed. Methods: A respective analysis was performed comparing the perioperative parameters and outcome of 20 patients who underwent pancreaticoduodenectomy with a gross suspected cancer residue and 30 patients who underwent a surgical bypass, all of the patients were diagnosed as in advanced stages intra-operatively. Results: The two groups were comparable with patient characteristics, including age, gender, initial symptoms and concomitant major organ diseases. Tumors are similar in size and intra-operatively diagnosed as in advanced stages in both groups. All of the patients in the resection group were microscopically proved having cancer residue. One postoperative mortality occurred in the resection group (5%), zero in the bypass group (P > 0.05). Overall complications were significantly higher in the resection group (30% vs. 0, P < 0.01), including 2 patients developed Acute Respiratory Distress Syndrome (ARDS), zero in the bypass group (P < 0.01); hemorrhage and transfusions in the resection group were much more than that in the bypass group (P < 0.05). Hospital stay after resection was significantly longer than bypass (20 vs. 12 days, P < 0.01). Hospital fee after resection was 4 times more than after bypass (median 61.500 vs. 15. 300 yuan, P < 0.01). Survival was significantly longer after resection (median 12.2 vs. 7.1 months, P < 0.01). Conclusion: Our results show that palliative resection in advanced pancreatic carcinoma lengthens the survival time of the patients, but this is paid for significantly higher complications than bypass. 相似文献
86.
手术中常用体位垫来调整体位及预防褥疮,但以往使用的软垫、海绵垫等却不可根据手术及术中的要求来调节高度,我科对其进行研究并利用现有材料,将其改进制成可调节型充气体位垫,投入临床试用,效果较好。现介绍如下。1材料与制作取上海百特医疗用品有限公司生产的3L容量的氯化钠溶液软包装袋一个,将其中一个出口封闭,使其不漏气。将一根长30cm~50cm长的橡胶管固定于另一个出口,使其不漏气,并将输血器调节器穿于橡胶管上,调节滚轴,起开关作用。连接气压止血器充气,即成可调节型充气调节体位垫。2使用方法根据手术要求将橡胶管连接于气压止血器… 相似文献
87.
88.
89.
90.
Chad G. Ball Andrew W. Kirkpatrick Matthew Smith Robert H. Mulloy Leonard Tse Ian B. Anderson 《European journal of trauma and emergency surgery》2007,33(5):550-552
Abstract We report a case of SMV injury in a critically ill patient. The patient was a 19-year-old woman involved in a motor vehicle
collision. Her injuries included grade II splenic and renal lacerations, devascularized and lacerated right and transverse
colon, a transected transverse mesocolon, a massive shear injury of her abdominal wall, and two partial SMV transections.
At initial damage control laparotomy, the SMV was ligated, the devascularized bowel resected and a temporary abdominal closure
applied. At re-operation, a mesocaval shunt using saphenous vein was employed. The shunt failed and the patient required a
saphenous vein jump graft. Although visceral vascular injuries are rare, ligation of the SMV in a damage control situation
is acceptable. This case study is the first to discuss appropriate treatment when interruption to a patient's collateral visceral
venous drainage limits the surgeon’s ability to ligate. In these situations, bypass shunts may be successful. 相似文献